U.S. Markets for Pharmacologic and Device-Based Approaches to Pain Management
U.S. Markets for Pharmacologic and Device-Based Approaches to Pain Management
$4,750.00
More than 40% of people in the U.S. say they have experienced recent pain, with 8% suffering from chronic pain. Direct healthcare costs associated with the treatment of pain total nearly $300 billion annually.
Publisher: Medtech Insight
- Description
- Contents
- Samples
More than 40% of people in the U.S. say they have experienced recent pain, with 8% suffering from chronic pain. Direct healthcare costs associated with the treatment of pain total nearly $300 billion annually, with indirect costs such as reduced worker productivity contributing another $300 billion in costs. Multidisciplinary pain management plans may involve the use of pharmacologic, device-based, or alternative therapies; a combination of these modalities often is required to achieve optimum pain relief, particularly for those suffering from chronic pain.
This new report by Medtech Insight presents a detailed overview of the U.S. pain management market. Major topics covered by this report include nonprescription analgesics (e.g., systemic drugs such as acetaminophen and NSAIDs, as well as topical drugs such as amino acids and esters, capsaicin, and methyl and trolamine salicylates), prescription analgesics (e.g., prescription NSAIDs, opioids, combination drugs, antimigraine drugs, adjuvant analgesics, and anesthetics), electrical stimulators (e.g., TENS units and neurostimulators such as occipital nerve, neuromuscular, and spinal cord stimulators), and infusion pumps (e.g., implantable and external pumps).
EXECUTIVE SUMMARY …………………………………………………………………………. ES-1
i. Pain Management Pharmaceuticals ……………………………………….. ES-1
a. Nonprescription Analgesics and Anesthetics ……………… ES-2
i. Nonprescription Systemic Analgesics ………… ES-2
ii. Nonprescription Topical Analgesics …………… ES-3
b. Prescription Analgesics and Anesthetics …………………… ES-3
i. Prescription Non-Steroidal Anti-Inflammatory Drugs …………………………… ES-4
ii. Opioid Analgesics ……………………………………. ES-4
iii. Opioid/Nonopioid Combination Analgesics …. ES-5
iv. Antimigraine Analgesics …………………………… ES-5
v. Adjuvant Analgesics ………………………………… ES-6
vi. General, Regional, and Local Anesthetics ….. ES-6
c. Market Forecast ……………………………………………………. ES-7
ii. Pain Management Devices ……………………………………………………. ES-8
a. Electrical Stimulators ……………………………………………… ES-8
i. Transcutaneous Electrical Nerve Stimulators ……………………………………. ES-8
ii. Neurostimulators …………………………………… ES-11
b. Analgesia Infusion Pumps …………………………………….. ES-12
i. Implantable Analgesia Infusion Pumps …….. ES-12
ii. External Analgesia Infusion Pumps ………….. ES-13
c. Market Forecast ………………………………………………….. ES-15
iii. Combined Market Forecast …………………………………………………. ES-15
Exhibit ES-1: Pain Management Pharmaceuticals, Market Forecast, 2015-2020 ………………………………………………………………………….. ES-9
Exhibit ES-2: Pain Management Devices, Market Forecast, 2015-2020 ………… ES-16
Exhibit ES-3: Pain Management Pharmaceuticals and Devices, Combined Market Forecast, 2015 through 2020 …………………….. ES-18
1. PAIN MANAGEMENT PHARMACEUTICALS …………………………………….. 1-1
1.1 Market Analysis ……………………………………………………………………… 1-1
1.1.1 Nonprescription Analgesics and Anesthetics ………………… 1-1
1.1.1.1 Combined Market Forecast …………………………. 1-2
U.S. Markets for Pharmacologic and
Device-Based Approaches to Pain Management Table of Contents
2016 Medtech Insight ii #A377
1.1.1.2 Nonprescription Systemic Analgesics …………… 1-2
1.1.1.2.1 Acetaminophen ………………………. 1-2
1.1.1.2.2 Nonprescription Nonsteroidal Anti-Inflammatory Drugs ………….. 1-4
1.1.1.2.2.1 Aspirin ……………….. 1-4
1.1.1.2.2.2 Ibuprofen ……………. 1-5
1.1.1.2.2.3 Ketoprofen ………….. 1-6
1.1.1.2.2.4 Naproxen ……………. 1-6
1.1.1.2.3 Market Forecast ……………………… 1-7
1.1.1.2.4 Competitive Analysis ……………… 1-10
1.1.1.3 Nonprescription Topical Analgesics and Anesthetics ……………………………………….. 1-10
1.1.1.3.1 Amino Amides and Esters ………. 1-12
1.1.1.3.2 Capsaicin …………………………….. 1-12
1.1.1.3.3 Methyl and Trolamine Salicylates ……………………………. 1-13
1.1.1.3.4 Topical Patches ……………………. 1-13
1.1.1.3.5 Market Forecast ……………………. 1-14
1.1.1.3.6 Competitive Analysis ……………… 1-14
1.1.2 Prescription Analgesics and Anesthetics ……………………. 1-14
1.1.2.1 Combined Market Forecast ……………………….. 1-18
1.1.2.2 Prescription Nonsteroidal Anti-Inflammatory Drugs ……………………………. 1-18
1.1.2.2.1 Acetic Acid Derivatives ………….. 1-18
1.1.2.2.2 Anthranilic Acid Derivatives ……. 1-21
1.1.2.2.3 Cyclooxygenase-2 Selective Inhibitors ………………… 1-21
1.1.2.2.4 Enolic Acid Derivatives ………….. 1-22
1.1.2.2.5 Propionic Acid Derivatives ……… 1-22
1.1.2.2.6 Salicylic Acid Derivatives ……….. 1-23
1.1.2.2.7 Market Forecast ……………………. 1-23
1.1.2.2.8 Competitive Analysis ……………… 1-25
1.1.2.3 Opioid Analgesics …………………………………….. 1-25
1.1.2.3.1 Buprenorphine ……………………… 1-27
1.1.2.3.2 Butorphanol …………………………. 1-28
1.1.2.3.3 Codeine ………………………………. 1-28
1.1.2.3.4 Fentanyl ………………………………. 1-28
Exhibit ES-1: (Continued)
Pain Management Pharmaceuticals, Market Forecast, 2015-2020
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
blisibimod 
Sign up to the